A higher dose of anti-T-lymphocyte globulin (ATLG) significantly outperformed a lower dose in preventing graft-vs-host ...

New medications are the first to benefit from initiative that aims to speed up access to oncology breakthroughs ...

The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, citing a lack of inventive ...

McKeesport-area residents like Patrick McBride don't just anticipate a diagnosis, they brace for exhaustion. When illness ...

Incyte shares are trading up 0.35% at $104.75 at the time of this writing on Thursday morning. Since the current price is ...

Debt Management: Incyte's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less ...

The Indian Patent Office rejected AbbVie’s patent application for cancer drug Venetoclax (Venclexta), a decision expected to ease the entry of lower-cost generics.

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

Herbicide RoundupTM, announced that the controversial herbicide glyphosate would be phased out of consumer products and ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Then you have the fact that clinical trials often underrepresent minorities. This can lead to skewed AI models, with 80 ...